HK1206758A1 - 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer 2--2345--1h-[b][14] - Google Patents

2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer 2--2345--1h-[b][14]

Info

Publication number
HK1206758A1
HK1206758A1 HK15107408.4A HK15107408A HK1206758A1 HK 1206758 A1 HK1206758 A1 HK 1206758A1 HK 15107408 A HK15107408 A HK 15107408A HK 1206758 A1 HK1206758 A1 HK 1206758A1
Authority
HK
Hong Kong
Prior art keywords
diazepines
benzo
tetrahydro
oxo
cancer
Prior art date
Application number
HK15107408.4A
Other languages
English (en)
Chinese (zh)
Inventor
Andrew F Donnell
Robert Francis Kester
Yan Lou
John Anthony Moliterni
Stacy Remiszewski
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HK1206758A1 publication Critical patent/HK1206758A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
    • C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
    • C07D243/24—Oxygen atoms
    • C07D243/26—Preparation from compounds already containing the benzodiazepine skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15107408.4A 2012-09-19 2015-08-03 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer 2--2345--1h-[b][14] HK1206758A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261702765P 2012-09-19 2012-09-19
PCT/EP2013/069080 WO2014044622A1 (en) 2012-09-19 2013-09-16 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer

Publications (1)

Publication Number Publication Date
HK1206758A1 true HK1206758A1 (en) 2016-01-15

Family

ID=49253260

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107408.4A HK1206758A1 (en) 2012-09-19 2015-08-03 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer 2--2345--1h-[b][14]

Country Status (12)

Country Link
US (1) US9422331B2 (pt)
EP (1) EP2897972B1 (pt)
JP (1) JP6302912B2 (pt)
KR (1) KR20150058222A (pt)
CN (1) CN104470940B (pt)
BR (1) BR112015004547A8 (pt)
CA (1) CA2877188A1 (pt)
ES (1) ES2613858T3 (pt)
HK (1) HK1206758A1 (pt)
MX (1) MX2015003188A (pt)
RU (1) RU2015112192A (pt)
WO (1) WO2014044622A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20151083A1 (es) * 2012-12-11 2015-08-06 Hoffmann La Roche Compuestos dimericos
RU2016122563A (ru) * 2013-11-18 2017-12-25 Ф. Хоффманн-Ля Рош Аг Тетрагидробензодиазепиноны
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
EP3458101B1 (en) * 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
AU2018338314A1 (en) 2017-09-22 2020-04-09 Kymera Therapeutics, Inc Protein degraders and uses thereof
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES OF THE LATEST
JP2021508703A (ja) 2017-12-26 2021-03-11 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. CRBN LIGANDS AND THEIR USES
EP3817748A4 (en) 2018-07-06 2022-08-24 Kymera Therapeutics, Inc. TRICYCLIC CRBN LIGANDS AND USES THEREOF
SG11202105424PA (en) 2018-11-30 2021-06-29 Kymera Therapeutics Inc Irak degraders and uses thereof
SG11202110829YA (en) 2019-04-05 2021-10-28 Kymera Therapeutics Inc Stat degraders and uses thereof
EP3989966A4 (en) 2019-06-28 2023-09-27 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
IL293917A (en) 2019-12-17 2022-08-01 Kymera Therapeutics Inc Iraq joints and their uses
EP4076524A4 (en) 2019-12-17 2023-11-29 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
WO2021133920A1 (en) 2019-12-23 2021-07-01 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
CN115776887A (zh) 2020-03-19 2023-03-10 凯麦拉医疗公司 Mdm2降解剂和其用途
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2022120355A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead degraders and uses thereof
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
AU2022378463A1 (en) 2021-10-25 2024-05-09 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206235A (en) * 1991-03-20 1993-04-27 Merck & Co., Inc. Benzo-fused lactams that promote the release of growth hormone
JPH08208627A (ja) * 1994-04-29 1996-08-13 Takeda Chem Ind Ltd 縮合複素環化合物またはその塩、その製造法および剤
BRPI0611922A2 (pt) * 2005-06-08 2010-10-05 Novartis Ag compostos orgánicos
WO2007101347A1 (en) * 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TW200914457A (en) * 2007-05-31 2009-04-01 Kyowa Hakko Kogyo Kk Pyrimidodiazepinone derivative
US8372885B2 (en) 2008-09-17 2013-02-12 Novartis Ag Organic compounds and their uses
CN104507913B (zh) * 2012-07-13 2017-07-28 霍夫曼-拉罗奇有限公司 抗增殖的苯并[b]氮杂*‑2‑酮
US9394263B2 (en) * 2012-08-09 2016-07-19 F. Hoffmann-La Roche Ag Substituted hetero-azepinones
PE20151083A1 (es) * 2012-12-11 2015-08-06 Hoffmann La Roche Compuestos dimericos

Also Published As

Publication number Publication date
MX2015003188A (es) 2015-07-17
CN104470940B (zh) 2018-10-16
US20150225449A1 (en) 2015-08-13
KR20150058222A (ko) 2015-05-28
US9422331B2 (en) 2016-08-23
BR112015004547A2 (pt) 2017-07-04
CA2877188A1 (en) 2014-03-27
RU2015112192A (ru) 2016-11-10
CN104470940A (zh) 2015-03-25
WO2014044622A1 (en) 2014-03-27
EP2897972B1 (en) 2016-11-30
JP6302912B2 (ja) 2018-03-28
BR112015004547A8 (pt) 2018-01-23
ES2613858T3 (es) 2017-05-26
JP2015528483A (ja) 2015-09-28
EP2897972A1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
HK1206758A1 (en) 2-oxo-2,3,4,5-tetrahydro-1 h-benzo[b]diazepines and their use in the treatment of cancer 2--2345--1h-[b][14]
HK1216251A1 (zh) 吡唑並吡咯烷衍生物及其治病作用
HK1170485A1 (zh) -噻唑烷- -酮衍生物及其在癌症治療中的用途
HK1168091A1 (en) Oxazine derivatives and their use in the treatment of neurological disorders
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
IL244902A0 (en) Derivatives of aminochroman, aminothiochroman and amino-1,2,3,4-tetrahydroquinoline, pharmaceutical compositions containing them and their use in treatment
IL239007A0 (en) Use of Aribolin to treat breast cancer
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
IL238481A0 (en) Cancer treatment using synthetic lethal approaches
HK1212255A1 (en) Artemisinin and its derivatives for use in the treatment of kidney disease
PT2872176T (pt) Carboranilporpirinas para utilização no tratamento de cancro
EP2744786A4 (en) SUBSTITUTED 2-IMIDAZOLIDINONE AND 2-IMIDAZOLONE AND THEIR USE IN THE TREATMENT OF CANCER
GB201718726D0 (en) Phytocannabinoids in the treatment of cancer
EP2833901A4 (en) POLYPEPTIDES AND THEIR USE IN THE TREATMENT OF METANEUMOVIRUS INFECTION (MPV)
AU344548S (en) Guitar in the shape and features of the guitar headstock and body
HK1209073A1 (en) Plod-2 stimulators and their use in the treatment of skin plod-2
AP2015008849A0 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of disease
CA139668S (en) Convertible jacket/bag
HUP1000688A2 (en) Use of trifluoro-phthalimides in the treatment of cancer
GB201008041D0 (en) Absorbent article and underwear primer
GB201015789D0 (en) Peptides and their use in the treatment